FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W774595448> ?p ?o ?g. }

• W774595448 abstract "As a result of improvements in DNA and RNA sequencing techniques the genomic structure of estrogen receptor positive breast cancer is increasingly well documented, but extracting clinically actionable information from these complex data sets has proved fraught with difficulties. Barriers to progress include the lack of pharmacological hypotheses for novel luminal breast cancer tumor suppressor genes (e.g. MAP3K1, MLL3, SF3B1); 2) a lack of a full understanding of interactions between mutation status, the prognosis of ER+ breast cancer, and the effectiveness of endocrine therapy; 3) an inadequate collection of patient-derived xenograft (PDX) models for luminal breast cancer that fully encompass the heterogeneity of the disease; 4) the logistical barriers of developing adjuvant strategies to exploit rare drivers present in less than 5% of tumor samples; 5) insufficient genomic discovery efforts directed towards samples accrued from patients suffering from endocrine therapy resistant disease progression and 6) an incomplete understanding of how complex somatic genotypes drive the biochemical events responsible for the “hallmarks” of luminal cancer. To better address these issues, five areas of investigation will be discussed: 1) somatic mutation diagnosis in DNA from primary breast cancer samples from patients treated with adjuvant tamoxifen and followed for over 20 years; 2) DNA and RNA sequencing of samples accrued from patients treated with neoadjuvant endocrine therapy to define the molecular origins of intrinsic aromatase inhibitor resistance and to identify pharmacological hypothesis; 3) efforts to expand and catalog patient-derived xenografts from ER+ breast cancers, including the use of mass spectrometry-based analysis of their proteomes and phosphoproteomes to expand our knowledge of the biochemistry of individual tumors; 4) a functional and pharmacological investigation of mutations in ESR1, including resistance-activating chromosomal translocations, and 5) the development of a neoadjuvant endocrine therapy strategy that identifies patients with intrinsic endocrine therapy resistance within a month of starting treatment so that they can be triaged to mutation-matched investigational treatment. Citation Format: Matthew J. Ellis. Genome-Directed Therapeutics for Endocrine Therapy Resistant ER+ Breast Cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr PL-1." @default.
• W774595448 created "2016-06-24" @default.
• W774595448 creator A5057135409 @default.
• W774595448 date "2015-04-30" @default.
• W774595448 modified "2023-09-27" @default.
• W774595448 title "Abstract PL-1: Genome-Directed Therapeutics for Endocrine Therapy Resistant ER+ Breast Cancer" @default.
• W774595448 doi "https://doi.org/10.1158/1538-7445.sabcs14-pl-1" @default.
• W774595448 hasPublicationYear "2015" @default.
• W774595448 type Work @default.
• W774595448 sameAs 774595448 @default.
• W774595448 citedByCount "0" @default.
• W774595448 crossrefType "proceedings-article" @default.
• W774595448 hasAuthorship W774595448A5057135409 @default.
• W774595448 hasConcept C121608353 @default.
• W774595448 hasConcept C126322002 @default.
• W774595448 hasConcept C143998085 @default.
• W774595448 hasConcept C2776166826 @default.
• W774595448 hasConcept C2777176818 @default.
• W774595448 hasConcept C2779134260 @default.
• W774595448 hasConcept C502942594 @default.
• W774595448 hasConcept C530470458 @default.
• W774595448 hasConcept C60644358 @default.
• W774595448 hasConcept C71924100 @default.
• W774595448 hasConcept C86803240 @default.
• W774595448 hasConceptScore W774595448C121608353 @default.
• W774595448 hasConceptScore W774595448C126322002 @default.
• W774595448 hasConceptScore W774595448C143998085 @default.
• W774595448 hasConceptScore W774595448C2776166826 @default.
• W774595448 hasConceptScore W774595448C2777176818 @default.
• W774595448 hasConceptScore W774595448C2779134260 @default.
• W774595448 hasConceptScore W774595448C502942594 @default.
• W774595448 hasConceptScore W774595448C530470458 @default.
• W774595448 hasConceptScore W774595448C60644358 @default.
• W774595448 hasConceptScore W774595448C71924100 @default.
• W774595448 hasConceptScore W774595448C86803240 @default.
• W774595448 hasLocation W7745954481 @default.
• W774595448 hasOpenAccess W774595448 @default.
• W774595448 hasPrimaryLocation W7745954481 @default.
• W774595448 hasRelatedWork W1607879668 @default.
• W774595448 hasRelatedWork W1835516666 @default.
• W774595448 hasRelatedWork W2022186931 @default.
• W774595448 hasRelatedWork W2032040083 @default.
• W774595448 hasRelatedWork W2039143946 @default.
• W774595448 hasRelatedWork W2087644802 @default.
• W774595448 hasRelatedWork W2089315453 @default.
• W774595448 hasRelatedWork W2168839110 @default.
• W774595448 hasRelatedWork W2283998212 @default.
• W774595448 hasRelatedWork W2460590704 @default.
• W774595448 hasRelatedWork W2513858874 @default.
• W774595448 hasRelatedWork W2586889430 @default.
• W774595448 hasRelatedWork W2617782212 @default.
• W774595448 hasRelatedWork W2792004124 @default.
• W774595448 hasRelatedWork W2944384594 @default.
• W774595448 hasRelatedWork W2946449192 @default.
• W774595448 hasRelatedWork W2972666684 @default.
• W774595448 hasRelatedWork W3012014129 @default.
• W774595448 hasRelatedWork W3044002837 @default.
• W774595448 hasRelatedWork W3213772653 @default.
• W774595448 isParatext "false" @default.
• W774595448 isRetracted "false" @default.
• W774595448 magId "774595448" @default.
• W774595448 workType "article" @default.